All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a healthcare professional. If you are a patient or carer, please visit the Lymphoma Coalition.

  TRANSLATE

The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

The Lymphoma Hub
Brought to you by Scientific Education Support

The Lymphoma Hub is an independent medical education platform, sponsored by Roche, AbbVie, BeOne, Miltenyi Biomedicine, Thermo Fisher, Nurix Therapeutics and Caribou Biosciences and supported through independent educational grants from Incyte, Bristol Myers Squibb, Lilly USA, LLC, Pfizer and Takeda Pharmaceuticals U.S.A., Inc. Funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.

View all

Now you can support HCPs in making informed decisions for their patients

Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.

Find out more
View on  

Important announcement

🚨 NEWS🚨

China’s NMPA approves an IND application for IASO208, an in vivo, lentiviral vector-based, CD20-targeted CAR T-cell therapy, for the treatment of patients with R/R B-cell non-Hodgkin lymphoma.

Read more: https://prn.to/4kb1IhL
View all drug updates

More drug updates

VIEW ALL
Important announcement
@FDA grants regenerative medicine advanced therapy and fast track designations to prizloncabtagene autoleucel (A-CAR039), an investigational autologous bispecific CD20/CD19-directed CAR T-cell therapy, for the treatment of patients with R/R LBCL. Read more: https://bit.ly/4sQW5Ym
Nov 11, 2026
Important announcement
@FDA grants 510(k) clearance to two ready-to-use flow cytometry clinical tests to aid the identification and diagnosis of B-cell NHL and CLL. Read more: https://prn.to/4sS1BtI
Nov 11, 2026
Important announcement
@FDA accepts and grants priority review to the supplemental new drug application for zanubrutinib, a BTK inhibitor, in combination with rituximab for the treatment of adults with previously untreated MCL. Read more: https://bit.ly/4sFQGU5
Nov 5, 2026
Important announcement
The phase I/II PALISADES-1 (NCT04989803) and phase III PALISADES-2 (NCT07479797) trials evaluating KITE-753, an investigational anti-CD19/CD20 CAR T-cell therapy, for the treatment of R/R DLBCL have been placed on partial clinical hold to evaluate differences in ICANS observed between the phase I and II safety findings. Read more: https://bit.ly/3WofhR8
Nov 3, 2026